NASDAQ: PTCT · Biotechnology

PTC Therapeutics (PTCT) fair value and price range

As of 16 Nov 2026, Faircurve's model values PTC Therapeutics (PTCT) at $74.62 a share. The stock last closed at $60.97, which puts the model's fair value 22.4% above the price. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.

Revalued . Price is the close of 16 Nov 2026. PTC Therapeutics, Inc.

The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.

Model fair value$74.62midpoint of 2,000 simulations
Last close$60.97NASDAQ: PTCT
Gap to fair value+22.4%fair value against price
Model verdictLow evidence gradeevidence grade: Low

This week, in three parts

What happenedThe run of 16 Nov 2026 moved the fair value from $76.37 to $74.62 (-2.3%).

What the model makes of itThe price of $60.97 is 22.4% below it. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.

What's nextNext report on 18 Feb 2027. Options prices imply a move of about 16% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.

What price range does the model give PTCT?

The calibrated range for PTCT over 63 trading days is $50.90 to $73.70. It sits around the last close, and its width comes from the volatility that PTCT's own options imply (55% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.

The model's own simulated range, from the 20th to the 80th percentile of its runs, is $46.51 to $113.95. In 61% of the simulations the fair value came out above the price the model ran on.

$26.67$216.49
Spread of the 2,000 simulated fair values. Solid line: the midpoint, $74.62. Dashed line: the last close, $60.97.

Faircurve Insights · 16 Nov 2026

PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development and commercialisation of innovative therapies for patients with rare genetic disorders.

Faircurve's model gives a fair value of $74.62 a share on 16 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $76.37, so the fair value moved -2.3%. The calibrated range over 63 trading days is $53.75 to $75.63, built from the volatility implied by the stock's options. The range is calibrated weekly against realised prices, using 8,038 past valuations refreshed on 14 Nov 2026. Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence as low, so no verdict is shown. The grade covers how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say whether the fair value is right.

The model's overall quality score is 41 out of 100, a composite of six factors. Growth quality stands out at 62, with trailing revenue growth of 114.5% against a peer median of 33.9%. Profitability scores 20, with ROIC of -215.9% against a peer median of -14.0%. The model compares the company with Protagonist Therapeutics, Inc. (PTGX), Acadia Pharmaceuticals Inc. (ACAD), ADMA Biologics, Inc. (ADMA) and Vericel Corporation (VCEL).

Written from the figures on this page for the 16 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.

The Global Pulse

Faircurve's note after each US session, in your inbox. No account needed.

When does PTCT report earnings, and how has the stock reacted?

PTC Therapeutics's next earnings report is scheduled for 18 Feb 2027. Companies can move their dates.

Options prices on 16 Nov 2026 imply a move of about 12.7% in either direction through the nearest expiry, about 31 days out. That is the size the market is pricing, not a direction. PTCT's 30 day implied volatility works out to about 15.8% over one month.

Around its last 8 reports: what the options market priced, and what followed

Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across PTCT's last 8 reports, ignoring direction, was 8.6%.

0%5%10%15%20%no quote8.4%27 Feb '2517.9%11.6%7 Aug '25no quote5.7%4 Nov '25no quote2.5%19 Feb '26no quote10.7%7 May '26no quote8.7%30 Jul '2617.7%4.8%29 Oct '2613.9%13.3%3 Nov '26priced before the reportthe move that followed
What the options market priced for each report, against the size of the move that followed. Priced: the move implied by options expiring after the report, on the last quote before it. Followed: the close before the report to the close after. Sizes only, no direction.

What the options market has priced for a month's move in PTCT

5%10%15%20%25%3 Nov '26 report29 Oct '26 report30 Jul '26 report7 May '26 report19 Feb '26 report16% at 16 Nov '2617 Nov '2516 Nov '26
What the options market priced for a month's move (30-day implied volatility, scaled to one month). It read 15% on 17 Nov 2025, reached 22% on 1 Apr 2026 and reads 16% on 16 Nov 2026. The marks are report dates.

How does PTCT score on business quality?

PTC Therapeutics's overall quality score is 41 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.

FactorScore (0 to 100)Headline measurePeer median
ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend.20-215.9%ROIC-14.0%
Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash).50
Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes.62114.5%Revenue growth, trailing33.9%
Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks.540.0%Net buybacks / market value0.0%
Balance sheetNet debt to EBITDA and interest coverage.440.73xNet debt / EBITDA
StabilityDownside volatility of the EBITDA margin over the last five years.2524.2 ptsEBITDA margin downside volatility, 5y51.4 pts

How does PTCT compare with similar companies?

The companies in biotechnology closest to PTC Therapeutics in market value, each on the same model and the same date.

CompanyLast closeModel fair valueGapModel verdict
LGND Ligand Pharmaceuticals Incorporated$301.71$282.99-6.2%Low evidence grade
ARWR Arrowhead Pharmaceuticals, Inc.$44.21$53.67+21.4%Low evidence grade
CYTK Cytokinetics, Incorporated$53.17$63.03+18.5%Low evidence grade
PTGX Protagonist Therapeutics, Inc.$124.83$104.97-15.9%Overvalued
ACAD Acadia Pharmaceuticals Inc.$18.67$23.24+24.5%Undervalued
KRYS Krystal Biotech, Inc.$297.90$352.42+18.3%Low evidence grade
ADMA ADMA Biologics, Inc.$13.47$15.96+18.5%Undervalued
VCEL Vericel Corporation$57.48$65.96+14.8%Fairly valued

What the comparable companies' multiples alone would give for PTCT, the peer-implied price, is $152.96 a share on this run. The fair value weighs that against the company's own multiple.

All biotechnology stocks ranked by gap to fair value

PTC Therapeutics at a glance

PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders.

Market value
$5.3B
Sector
Healthcare
Industry
Biotechnology
Revenue expected, next twelve months
$1.4B
Consensus revenue growth, next fiscal year
-23.7%
Analysts with estimates
7
Beta to the US market
0.68
First valued by Faircurve
11 Jul 2026

How the fair value is worked out: the model prices PTC Therapeutics on the value of the whole business, debt included, against the revenue analysts expect next year (forward EV/Sales), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.

What changed in the latest valuation?

On 7 Nov 2026 the model's fair value for PTCT was $76.37. As of 16 Nov 2026 it is $74.62, a change of -2.3%. The model revalues every stock it covers each week, and again after an earnings report.

Questions about PTC Therapeutics's valuation

Is PTC Therapeutics stock undervalued or overvalued?

Faircurve's model puts PTCT's fair value at $74.62 a share against a last close of $60.97, as of 16 Nov 2026. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.

What is PTCT's fair value?

$74.62 a share as of 16 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $46.51 to $113.95.

What price range does the model give PTCT?

$50.90 to $73.70 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.

When does PTC Therapeutics report earnings next?

The next report is scheduled for 18 Feb 2027. Companies can move their dates.

How much has PTCT moved on past earnings reports?

Across its last 8 reports the median two session move was 8.6%, ignoring direction. The largest was +13.3% around the report of 3 Nov 2026.

How confident is the model in this valuation?

The model's evidence grade for PTCT is low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.

The model's own ideas on PTCT

The model holds no idea open on PTCT today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on PTCT with their outcomes. A free account is enough.

Keep reading